Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMTPH.L Regulatory News (MTPH)

  • There is currently no data for MTPH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

9 Dec 2014 15:37

RNS Number : 2902Z
Midatech Pharma PLC
09 December 2014
 



 

For filings with the FCA include the annex

For filings with issuer exclude the annex

 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached:

 

Midatech Pharma Plc

2. Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

Yes

 

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached.

 

 

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

 

An event changing the breakdown of voting rights

 

Other (please specify):

 

3. Full name of person(s) subject to thenotification obligation:

Legal & General Group Plc (L&G)

4. Full name of shareholder(s)  (if different from 3.):

Legal & General Assurance Society Limited (LGAS & LGPL)

 

5. Date of the transaction and date onwhich the threshold is crossed orreached:

 

08 December 2014

6. Date on which issuer notified:

09 December 2014

7. Threshold(s) that is/are crossed orreached:

 

L&G (Above 3%)

 

8. Notified details:

 

A: Voting rights attached to shares

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

 

Numberof shares

Number of votingrights

% of voting rights

Direct

Indirect

Direct

Indirect

ORD GBP 0.00005

 Below 3%

 

(As on First notification under DTR Source Book)

 1,123,500

 1,123,500

-

4.04%

-

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

 

Type of financialinstrument

 

Expirationdate

 

Exercise/Conversion Period

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

 

% of votingrights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments

Resulting situation after the triggering transaction

 

Type of financialinstrument

 

 

Exercise price

 

Expiration date

 

Exercise/Conversion period

 

Number of voting rights instrument refers to

 

 

% of voting rights

 

 

 

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

 1,123,500

4.04%

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable:

 

Legal & General Group Plc (Direct and Indirect) (Group)

Legal & General Investment Management (Holdings) Limited (LGIMH) (Direct and Indirect)

Legal & General Investment Management Limited (Indirect) (LGIM)

Legal & General Group Plc (Direct) (L&G) ( 1,123,500 -4.04% = LGAS, LGPL & PMC)

Legal & General Investment Management (Holdings) Limited (Direct) (LGIMHD)

Legal & General Insurance Holdings Limited (Direct) (LGIH) ( 1,123,500 - 4.04%= LGAS & LGPL)

Legal & General Assurance (Pensions Management) Limited (PMC)

Legal & General Assurance Society Limited (LGAS & LGPL) ( 1,123,500 - 4.04%= LGAS & LGPL)

Legal & General Pensions Limited (Direct) (LGPL)

Proxy Voting:

10. Name of the proxy holder:

N/A

11. Number of voting rights proxy holder will ceaseto hold:

N/A

12. Date on which proxy holder will cease to holdvoting rights:

N/A

13. Additional information:

Notification using the total voting rights figure of  27,794,260

14. Contact name:

Amy Williams (LGIM)

15. Contact telephone number:

020 2035 4097

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLTLBATMBJMBFI
Date   Source Headline
10th Mar 20235:52 pmRNSFurther re: Notice of General Meeting
8th Mar 20237:00 amRNSPosting of Circular and Notice of General Meeting
17th Feb 20237:00 amRNSHolding(s) in Company
16th Feb 20237:00 amRNSHolding(s) in Company
15th Feb 20232:49 pmRNSHolding(s) in Company
15th Feb 20231:36 pmRNSHolding(s) in Company
15th Feb 20231:26 pmRNSHolding(s) in Company
15th Feb 20238:05 amRNSClosing of $6.0m Private Placement & Broker Change
9th Feb 20235:10 pmRNSPrivate Placement Raising US$6.0 million
3rd Feb 20239:57 amRNSReceipt of NASDAQ Notice
23rd Jan 20234:40 pmRNSSecond Price Monitoring Extn
23rd Jan 20234:35 pmRNSPrice Monitoring Extension
23rd Jan 202312:00 pmRNSResult of General Meeting
16th Jan 202311:24 amRNSHolding(s) in Company
12th Jan 20237:00 amRNSPlanned Dose Escalation in MTX-110 Phase 1 Study
6th Jan 20237:00 amRNSPosting of Circular and Notice of General Meeting
19th Dec 202212:06 pmRNSHolding(s) in Company
19th Dec 202210:48 amRNSHolding(s) in Company
19th Dec 20227:00 amRNSClosing of Offering, Revised Terms, AIM & Webinar
14th Dec 20222:05 pmRNSSecond Price Monitoring Extn
14th Dec 20222:00 pmRNSPrice Monitoring Extension
13th Dec 20224:40 pmRNSSecond Price Monitoring Extn
13th Dec 20224:35 pmRNSPrice Monitoring Extension
13th Dec 20223:22 pmRNSProposed Acquisition of Bioasis Technologies Inc
14th Nov 20227:00 amRNSFirst Patient Enrolled in Phase 1 Study of MTX-110
18th Oct 20227:00 amRNSReceipt of NASDAQ Notification
20th Sep 202211:51 amRNSHolding(s) in Company
14th Sep 20221:57 pmRNSADR Ratio Change
14th Sep 20227:00 amRNSInterim results for the six months to 30 June 2022
21st Jun 20227:00 amRNSMTX110 Development for the Treatment of Glioma
20th Jun 20225:58 pmRNSDirectorate Change
20th Jun 20222:33 pmRNSResult of 2022 Annual General Meeting
10th Jun 20227:00 amRNSRetirement of Chairman and Proposed New Chairman
10th Jun 20227:00 amRNSMTX110 Study to be Presented at ISPNO 2022
1st Jun 202212:23 pmRNSFast Track Designation for MTX110 Development
24th May 202211:09 amRNSPosting of Annual Report & Notice of AGM
27th Apr 20221:00 pmRNSIssue of Equity for Employee Share Incentive Plan
26th Apr 20227:00 amRNSResults for the Year Ended 31 December 2021
14th Apr 202212:37 pmRNSReceipt of NASDAQ Notice
17th Mar 20227:00 amRNSExercise of Warrants and Issue of Equity
9th Mar 20227:00 amRNSR&D collaboration with Janssen on second molecule
8th Mar 20229:30 amRNSAppointment of Nominated and Financial Adviser
9th Feb 20221:53 pmRNSHolding(s) in Company
18th Jan 20224:18 pmRNSHolding(s) in Company
17th Jan 20227:00 amRNSExtension of Janssen collaboration re Q-Sphera
7th Jan 20225:37 pmRNSHolding(s) in Company
13th Dec 20219:43 amRNSIND Application for MTX110 Study in GBM Effective
3rd Dec 20217:00 amRNSMidatech presenting at MelloMonday
24th Nov 20217:00 amRNSMidatech presenting at the Shares/AJ Bell Webinar
17th Sep 20219:31 amRNSInterim results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.